|
Exhibit
10.2
FORM OF SECURITIES
PURCHASE AGREEMENT
This Securities Purchase
Agreement (this “ Agreement ”) is dated as of
February 7, 2008, between GTC Biotherapeutics, Inc., a
Massachusetts corporation (the “ Company ”), and
each purchaser identified on the signature pages hereto (each,
including its successors and assigns, a “ Purchaser
” and collectively the “ Purchasers
”).
WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an
effective registration statement under the Securities Act of 1933,
as amended (the “ Securities Act ”), the Company
desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this
Agreement.
NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement,
and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and each
Purchaser agree as follows:
ARTICLE I.
DEFINITIONS
1.1 Definitions . In
addition to the terms defined elsewhere in this Agreement, for all
purposes of this Agreement, the following terms have the meanings
set forth in this Section 1.1:
“ Action ”
shall have the meaning ascribed to such term in
Section 3.1(j).
“ Affiliate
” means any Person that, directly or indirectly through one
or more intermediaries, controls or is controlled by or is under
common control with a Person as such terms are used in and
construed under Rule 405 under the Securities Act. With respect to
a Purchaser, any investment fund or managed account that is managed
on a discretionary basis by the same investment manager as such
Purchaser will be deemed to be an Affiliate of such
Purchaser.
“ Beneficial
Owner ” means with respect to any securities, any Person
or any of such Person’s Affiliates, representatives or
associates, directly or indirectly, who
(i) “beneficially own” such securities as
determined pursuant to Rule 13d-3 under the Exchange Act,
(ii) has the right to acquire, vote or dispose of such
securities or (iii) has any agreement, arrangement or
understanding for the purpose of acquiring, holding, voting or
disposing of such securities.
“ Board of
Directors ” means the board of directors of the
Company.
“ Business Day
” means any day except any Saturday, any Sunday, any day
which is a federal legal holiday in the United States or any day on
which banking institutions in the State of New York are authorized
or required by law or other governmental action to
close.
1
“ Closing
” means the closing of the purchase and sale of the
Securities pursuant to Section 2.1.
“ Closing Date
” has the meaning ascribed to such term in
Section 2.1.
“ Closing Price
” means on any particular date (a) the last reported
closing bid price per share of Common Stock during regular trading
hours on such date on the Trading Market (as reported by Bloomberg
L.P. at 4:15 p.m. (New York City time)), or (b) if there is no
such price on such date, then the closing bid price on the Trading
Market on the date nearest preceding such date (as reported by
Bloomberg L.P. at 4:15 p.m. (New York City time)) , or (c) if
the Common Stock is not then listed or quoted on a Trading Market
and if prices for the Common Stock are then reported in the
“pink sheets” published by Pink Sheets LLC (or a
similar organization or agency succeeding to its functions of
reporting prices), the most recent bid price per share of the
Common Stock so reported, or (d) if the shares of Common Stock
are not then publicly traded the fair market value of a share of
Common Stock as determined by an independent appraiser selected in
good faith by the Purchasers of a majority of the Shares and any
outstanding Warrant Shares, in the aggregate, still held by the
Purchasers and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company.
“ Commission
” means the Securities and Exchange Commission.
“ Common Stock
” means the common stock of the Company, par value $0.01 per
share, and any other class of securities into which such securities
may hereafter be reclassified or changed into.
“ Common Stock
Equivalents ” means any securities of the Company or the
Subsidiary which would entitle the holder thereof to acquire at any
time Common Stock, including, without limitation, any debt,
preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for,
or otherwise entitles the holder thereof to receive, Common
Stock.
“ Company
Counsel ” means Edwards Angell Palmer & Dodge
LLP, with offices located at 111 Huntington Avenue, Boston,
Massachusetts 02199.
“ Disclosure
Schedules ” means the Disclosure Schedules of the Company
delivered concurrently herewith.
“ Discussion
Time ” has the meaning ascribed to such term in
Section 3.2(g).
“ DTC ”
means The Depositary Trust Company.
“ DWAC ”
has the meaning ascribed to such term in
Section 2.3(a).
“ Evaluation
Date ” has the meaning ascribed to such term in
Section 3.1(r).
2
“ Exchange Act
” means the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder.
“ Exempt
Issuance ” means the issuance of (a) shares of
Common Stock or options to employees, officers or directors of the
Company pursuant to any stock or option plan duly adopted for such
purpose, by a majority of the non-employee members of the Board of
Directors or a majority of the members of a committee of
non-employee directors established for such purpose,
(b) securities upon the exercise or exchange of or conversion
of any Securities issued hereunder and/or other securities issued
and outstanding on the date of this Agreement and exercisable or
exchangeable for or convertible into shares of Common Stock,
provided that such securities have not been amended since the date
of this Agreement to increase the number of such securities or to
decrease the exercise, exchange or conversion price of such
securities and (c) securities issued pursuant to acquisitions
or strategic transactions approved by a majority of the
disinterested directors of the Company, provided that any such
issuance shall only be to a Person which is, itself or through its
subsidiaries, an operating company in a business synergistic with
the business of the Company and in which the Company receives
benefits in addition to the investment of funds, but shall not
include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose
primary business is investing in securities.
“ FDA ”
has the meaning ascribed to such term in Section
3.1(ff).
“ FDCA ”
has the meaning ascribed to such term in
Section 3.1(ff).
“ MZRL ”
means Morse, Zelnick, Rose & Lander, LLP with offices
located at 405 Park Avenue, Suite 1401, New York New York
10022.
“ GAAP ”
shall have the meaning ascribed to such term in
Section 3.1(h).
“ Indebtedness
” shall have the meaning ascribed to such term in
Section 3.1(y).
“ Intellectual
Property Rights ” shall have the meaning ascribed to such
term in Section 3.1(o).
“ Liens ”
means a lien, charge, security interest, encumbrance, right of
first refusal, preemptive right or other restriction.
“ Material Adverse
Effect ” shall mean (i) a material adverse effect on
the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of
operations, assets, business, or financial condition of the Company
and the Subsidiary, taken as a whole; provided, however, that such
an effect shall not be deemed to have occurred based on low cash
position, continuing losses from operations or notice from the
Trading Market of non-compliance with the minimum bid price
requirement for continued listing, or (iii) a material adverse
effect on the Company’s ability to perform in any material
respect on a timely basis its obligations under any Transaction
Document.
3
“ Material
Permits ” shall have the meaning ascribed to such term in
Section 3.1(m).
“ Per Unit Purchase
Price ” equals $0.87.
“ Person ”
means an individual or corporation, partnership, trust,
incorporated or unincorporated association, joint venture, limited
liability company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind.
“ Pharmaceutical
Product ” has the meaning ascribed to such term in
Section 3.1(gg).
“ Placement
Agent ” means Rodman & Renshaw, LLC.
“ Proceeding
” means an action, claim, suit, investigation or proceeding
(including, without limitation, an informal investigation or
partial proceeding, such as a deposition), whether commenced or
threatened.
“ Prospectus
” means the prospectus dated May 2, 2007 contained in
the Registration Statement.
“ Prospectus
Supplement ” means the supplement (or supplements) to the
Prospectus relating to the placement of the Securities and the plan
of distribution thereof complying with Rule 424(b) under the
Securities Act and filed with the Commission and delivered by the
Company to each Purchaser at the Closing.
“ Purchaser
Party ” shall have the meaning ascribed to such term in
Section 4.8.
“ Registration
Statement ” means the registration statement (File
No. 333-142564) filed with the Commission on May 2, 2007
and declared effective by the Commission on May 18, 2007,
registering the issuance of the Shares, the Warrants and the
Warrant Shares by the Company.
“ Required
Approvals ” shall have the meaning ascribed to such term
in Section 3.1(e).
“ Rule 144
” means Rule 144 promulgated by the Commission pursuant to
the Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the
Commission having substantially the same effect as such
Rule.
“ SEC Reports
” shall have the meaning ascribed to such term in
Section 3.1(h).
“ Securities
” means the Shares, the Warrants and the Warrant
Shares.
“ Securities Act
” means the Securities Act of 1933, as amended, and the rules
and regulations promulgated thereunder.
4
“ Shares ”
means the shares of Common Stock issued or issuable to each
Purchaser pursuant to this Agreement and excludes the Warrant
Shares.
“ Short Sales
” means all “short sales” as defined in Rule 200
of Regulation SHO under the Exchange Act (but shall not be deemed
to include the location and/or reservation of borrowable shares of
Common Stock).
“ Subscription
Amount ” means, as to each Purchaser, the aggregate
amount to be paid for Units purchased hereunder as specified below
such Purchaser’s name on the signature page of this Agreement
and next to the heading “Subscription Amount,” in
United States dollars and in immediately available
funds.
“ Subsidiary
” means GTC Holdings Ltd., a Cayman Island entity, and shall,
where applicable, include any subsidiary of the Company formed or
acquired after the date hereof that is a “significant
subsidiary” as determined in accordance with Regulation
S-X.
“ Time of Sale
Information ” means the Prospectus, Prospectus
Supplements and any “free-writing prospectuses” (as
defined by Rule 405 under the Securities Act) filed by the Company
and delivered to the Purchaser on or prior to the date of this
Agreement.
“ Trading Day
” means a day on which the New York Stock Exchange is open
for trading.
“ Trading Market
” means any of the following markets or exchanges on which
the Common Stock is listed or quoted for trading: the American
Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global
Market, the Nasdaq Global Select Market, the New York Stock
Exchange or the OTC Bulletin Board and any successors to any of
such markets or exchanges.
“ Transaction
Documents ” means this Agreement and the Warrants and any
other documents or agreements to be delivered to, or entered into
with, the Purchasers and executed in connection with the
transactions contemplated hereunder.
“ Transfer Agent
” means American Stock Transfer & Trust Company, the
current transfer agent of the Company, with a mailing address of
6201 15 th Avenue, Brooklyn, New York 11219 and a
facsimile number of 718-921-8206, and any successor transfer agent
of the Company.
“ Unit ”
means a unit consisting of one Share of Common Stock and a common
stock purchase warrant to purchase one Warrant Share.
“ Variable Rate
Transaction ” has the meaning ascribed to such term in
Section 4.12(b).
“ Warrants
” means, collectively, the Common Stock purchase warrants, in
the form attached as Exhibit A hereto, delivered to the
Purchasers at the Closing in accordance with Section 2.3(b)
hereof, which Warrants shall be exercisable at any time on or after
six months after the date of the Warrants and have a term of
exercise equal to seven years.
5
“ Warrant Shares
” means the shares of Common Stock issuable upon exercise of
the Warrants.
ARTICLE II.
PURCHASE AND SALE
2.1 Closing
.
Upon the terms and subject to
the conditions set forth herein, the Company agrees to sell, and
the Purchasers, severally and not jointly, agree to purchase, up to
an aggregate of $6,000,000 worth of Units. On the third Trading Day
following the date of this Agreement or such other date as the
parties shall mutually agree (the “ Closing Date
”), (a) the Company and each Purchaser shall deliver the
items set forth in Section 2.4, (b) each Purchaser shall
deliver or caused to be delivered to the Company immediately
available funds equal to each Purchaser’s Subscription Amount
pursuant to Section 2.2 and (c) the Company shall deliver
or cause to be delivered to each Purchaser the Shares and a
certificate evidencing the Warrants purchased by such Purchaser
under the Agreement in accordance with Section 2.3 (the
“ Closing ”). The Closing shall occur at the
offices of MZRL or such other location as the parties shall
mutually agree.
2.2 Delivery of Funds
.
On the Closing Date, upon the
satisfaction by the Company of the conditions set forth in
Section 2.4(b) hereof, each Purchaser shall deliver to the
Company by wire transfer immediately available funds equal to the
Purchaser’s Subscription Amount to the following
account:
|
|
|
| ABA Routing No.: |
|
121-140-399 |
| Bank: |
|
Silicon
Valley Bank |
| Account No.: |
|
3300345727 |
| Beneficiary Name: |
|
GTC
Biotherapeutics, Inc. |
2.3 Delivery of Shares and
Warrants .
(a) Shares . On or
prior to the Closing Date, the Purchaser shall direct the
broker-dealer at which the account or accounts to be credited with
the Shares being purchased by such Purchaser are maintained (which
broker/dealer shall be a DTC participant) to set up a
Deposit/Withdrawal at Custodian (“ DWAC ”)
instructing the Transfer Agent to credit such account or accounts
by means of an electronic book-entry delivery on the Closing Date
with such number of Shares equal to the Purchaser’s
Subscription Amount divided by the Per Unit Purchase
Price.
Immediately upon receipt by
the Company of immediately available funds from each Purchaser
equal to such Purchaser’s Subscription Amount, the Company
shall direct the Transfer Agent to credit such Purchaser’s
account or accounts with the Shares pursuant to the information
contained in the DWAC.
6
(b) Warrants .
Immediately upon receipt by the Company of immediately available
funds from each Purchaser equal to such Purchaser’s
Subscription Amount, the Company shall also deliver or cause to be
delivered to such Purchaser (or to MZRL on behalf of the Purchaser)
an original certificate evidencing the Warrant registered in the
name of such Purchaser to purchase up to a number of shares of
Common Stock equal to 100% of such Purchaser’s Subscription
Amount divided by the Per Unit Purchase Price, with an exercise
price equal to $0.87, subject to adjustment as set forth in the
form attached as Exhibit A hereto.
2.4 Closing Conditions and
Deliverables .
(a) The obligations of the
Company hereunder in connection with the Closing are subject to the
following conditions being met:
(i) the accuracy in all
material respects on the Closing Date of the representations and
warranties of the Purchasers contained herein;
(ii) all obligations,
covenants and agreements of each Purchaser required to be performed
at or prior to the Closing Date shall have been performed;
and
(iii) the delivery to the
Company by or on behalf of each Purchaser, on or prior to the
Closing Date, of the following items:
(A) this Agreement duly
executed by such Purchaser; and
(B) such Purchaser’s
Subscription Amount by wire transfer to the account as specified in
writing by the Company.
(b) The respective
obligations of the Purchasers hereunder in connection with the
Closing are subject to the following conditions being
met:
(i) the accuracy in all
material respects on the Closing Date of the representations and
warranties of the Company contained herein;
(ii) all obligations,
covenants and agreements of the Company required to be performed at
or prior to the Closing Date shall have been performed;
(iii) the delivery by the
Company, on or prior to the Closing Date, of the following
items:
(A) this Agreement duly
executed by the Company;
(B) a legal opinion of
Company Counsel, substantially in the form of Exhibit B
attached hereto;
7
(C) a copy of the irrevocable
instructions to the Transfer Agent to deliver via DWAC Shares equal
to such Purchaser’s Subscription Amount divided by the Per
Unit Purchase Price, registered in the name of such
Purchaser;
(D) a copy of the certificate
issued by the Company evidencing the Warrant registered in the
Purchaser’s name; and
(E) the Prospectus and
Prospectus Supplement (which may be delivered in accordance with
Rule 172 under the Securities Act).
(iv) there shall have been no
Material Adverse Effect with respect to the Company since the date
hereof; and
(v) from the date hereof to
the Closing Date, trading in the Common Stock shall not have been
suspended by the Commission or the Company’s principal
Trading Market (except for any suspension of trading of limited
duration agreed to by the Company, which suspension shall be
terminated prior to the Closing), and, at any time prior to the
Closing Date, trading in securities generally as reported by
Bloomberg L.P. shall not have been suspended or limited, or minimum
prices shall not have been established on securities whose trades
are reported by such service, or on any Trading Market, nor shall a
banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any
material outbreak or escalation of hostilities or other national or
international calamity of such magnitude in its effect on, or any
material adverse change in, any financial market which, in each
case, in the reasonable judgment of each Purchaser, makes it
impracticable or inadvisable to purchase the Securities at the
Closing.
Each Purchaser’s
obligations are expressly not conditioned on the purchase of
Securities by any or all of the other Purchasers.
ARTICLE III.
REPRESENTATIONS AND
WARRANTIES
3.1 Representations and
Warranties of the Company . Except as set forth in the
Disclosure Schedules, which Disclosure Schedules shall be deemed a
part hereof and shall qualify any representation or otherwise made
herein to the extent of the disclosure contained in the
corresponding section of the Disclosure Schedule, the Company
hereby makes the following representations and warranties to each
Purchaser:
(a) Subsidiaries . The
Subsidiary is the Company’s only “significant
subsidiary” as determined in accordance with Regulation S-X.
Except as described in the SEC Reports, the Company owns, directly
or indirectly, all of the capital stock or other equity interests
of the Subsidiary free and clear of any Liens, and all of the
issued and outstanding shares of capital stock of the Subsidiary
are validly issued and are fully paid, non-assessable and free of
preemptive and similar rights to subscribe for or purchase
securities.
8
(b) Organization and
Qualification . The Company and the Subsidiary are each
entities duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of their
incorporation or organization (as applicable), with the requisite
power and authority to own and use their properties and assets and
to carry on their business as currently conducted. Neither the
Company nor the Subsidiary is in violation or default of any of the
provisions of their respective certificate or articles of
incorporation, bylaws or other organizational or charter documents.
Each of the Company and the Subsidiary is duly qualified to conduct
business and is in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business
conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good
standing, as the case may be, would not reasonably be expected to
result in a Material Adverse Effect and no Proceeding has been
instituted in any such jurisdiction revoking, limiting or
curtailing or seeking to revoke, limit or curtail such power and
authority or qualification.
(c) Authorization;
Enforcement . The Company has the requisite corporate power and
authority to enter into and to consummate the transactions
contemplated by each of the Transaction Documents and otherwise to
carry out its obligations hereunder and thereunder. The execution
and delivery of each of the Transaction Documents by the Company
and the consummation by it of the transactions contemplated thereby
have been duly authorized by all necessary action on the part of
the Company and no further action is required by the Company, the
Board of Directors or the Company’s stockholders in
connection therewith other than in connection with the Required
Approvals. Each Transaction Document to which the Company is a
party has been (or upon delivery will have been) duly executed by
the Company and, when delivered in accordance with the terms hereof
and thereof, will constitute the valid and binding obligation of
the Company enforceable against the Company in accordance with its
terms, except (i) as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as
indemnification and contribution provisions may be limited by
applicable law or public policy relating thereto.
(d) No Conflicts . The
execution, delivery and performance of the Transaction Documents by
the Company, the issuance and sale of the Securities and the
consummation by the Company of the other transactions contemplated
hereby and thereby do not and will not (i) conflict with or
violate any provision of the Company’s or the
Subsidiary’s certificate or articles of incorporation, bylaws
or other organizational or charter documents, or (ii) conflict
with, or constitute a default (or an event that with notice or
lapse of time or both would become a default) under, result in the
creation of any Lien upon any of the properties or assets of the
Company or the Subsidiary, or give to others any rights of
termination, amendment, acceleration or cancellation (with or
without notice, lapse of time or both) of, any agreement, credit
facility, debt or other instrument (evidencing a Company or
Subsidiary debt or otherwise) or other understanding to which the
Company or the Subsidiary is a party or by which any property or
asset of the Company or the Subsidiary is bound or affected, or
(iii) subject to
9
the Required Approvals,
conflict with or result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the
Company or a Subsidiary is subject (including federal and state
securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the
case of each of clauses (ii) and (iii), such as would not
reasonably be expected to result in a Material Adverse
Effect.
(e) Filings, Consents and
Approvals . The Company is not required to obtain any consent,
waiver, authorization or order of, give any notice to, or make any
filing or registration with, any court or other federal, state,
local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of the
Transaction Documents, other than (i) filings required
pursuant to Section 4.4 of this Agreement, (ii) the
filing with the Commission of the Prospectus Supplement,
(iii) application(s) to each applicable Trading Market for the
listing of the Shares and Warrant Shares for trading thereon in the
time and manner required thereby and (iv) such filings as are
required to be made under applicable Federal and state securities
laws (collectively, the “ Required Approvals
”).
(f) Issuance of the
Securities; Registration . The Securities are duly authorized
and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid
and nonassessable, free and clear of all Liens imposed by the
Company, other than restrictions on transfer provided for in the
Transaction Documents. The Warrant Shares, when issued in
accordance with the terms of the Warrants, will be validly issued,
fully paid and nonassessable, free and clear of all Liens imposed
by the Company, other than restrictions on transfer provided for in
the Transaction Documents. On the Closing Date, the Shares will be
listed and freely tradable, and the Warrants Shares will authorized
for listing, on the Trading Market. The Company has reserved from
its duly authorized capital stock the maximum number of shares of
Common Stock issuable pursuant to this Agreement and the Warrants.
The Company has prepared and filed the Registration Statement in
conformity with the requirements of the Securities Act, which
became effective on May 18, 2007, including the Prospectus,
and such amendments and supplements thereto as may have been
required to the date of this Agreement. The Registration Statement
is effective under the Securities Act and the Company has not
received any notice, or has any knowledge, of (i) the issuance
of any stop order by the Commission preventing or suspending the
effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus by the Commission or
(ii) the institution, or threat thereof, by the Commission of
any proceedings for that purpose. The Company, if required by the
rules and regulations of the Commission, proposes to file the
Prospectus Supplement, with the Commission pursuant to Rule 424(b).
At the time the Registration Statement and any amendments thereto
became effective, at the date of this Agreement and at the Closing
Date, the Registration Statement and any amendments thereto
conformed and will conform in all material respects to the
requirements of the Securities Act and did not and will not contain
any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which
they were made, not misleading; and the Prospectus, the Prospectus
Supplement and the free-writing prospectuses, if any, and any
amendments or
10
supplements thereto, each as
of its respective date, conformed and will conform in all material
respects to the requirements of the Securities Act and did not and
will not contain an untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements
therein, in light of the circumstances under which they were made,
not misleading.
(g) Capitalization .
The capitalization of the Company as of December 30, 2007 (the
last day of its most recently completed fiscal year) is set forth
in Schedule 3.1(g) hereto. Except (i) as a result of
the purchase and sale of the Securities, (ii) as described in
Schedule 3.1(g) or (iii) pursuant to the exercise of
employee stock options under the Company’s stock option
plans, the issuance of shares of Common Stock to employees pursuant
to the Company’s employee stock purchase plans and pursuant
to the conversion or exercise of securities exercisable,
exchangeable or convertible into Common Stock under any of the
Company’s equity incentive plans (the “ Common Stock
Equivalents ”), there are no outstanding options,
warrants, script rights to subscribe to, calls or commitments of
any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares
of Common Stock, or contracts, commitments, understandings or
arrangements by which the Company or the Subsidiary is or may
become bound to issue additional shares of Common Stock or Common
Stock Equivalents. Except as described in Schedule 3.1(g)
hereto, no Person has any right of first refusal, preemptive right,
right of participation, or any similar right to participate in the
transactions contemplated by the Transaction Documents, which right
has not been waived with respect to the transactions contemplated
by the Transaction Documents. Except as described in Schedule
3.1(g) hereto, the issuance and sale of the Securities will not
obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Purchasers) and will not
result in a right of any holder of Company securities to adjust the
exercise, conversion, exchange or reset price under any of such
securities. All of the outstanding shares of capital stock of the
Company are validly issued, fully paid and nonassessable, have been
issued in compliance with all federal and state securities laws,
and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase
securities. No further approval or authorization of any
stockholder, the Board of Directors or others is required for the
issuance and sale of the Securities. Except as described in, or
incorporated into, the Registration Statement, there are no
stockholders agreements, voting agreements or other similar
agreements with respect to the Company’s capital stock to
which the Company is a party or, to the knowledge of the Company,
between or among any of the Company’s
stockholders.
(h) SEC Reports; Financial
Statements . The Company has complied in all material respects
with requirements to file all reports, schedules, forms, statements
and other documents required to be filed by the Company under the
Exchange Act, including pursuant to Section 13(a) or 15(d)
thereof, for one year preceding the date hereof (or such shorter
period as the Company was required by law or regulation to file
such material) (the foregoing materials, including the exhibits
thereto and documents incorporated by reference therein, being
collectively referred to herein as the “ SEC Reports
”) on a timely basis or has received a valid extension of
such time of filing and has filed any such SEC
11
Reports prior to the
expiration of any such extension. As of their respective filing
dates, the SEC Reports complied in all material respects with the
requirements of the Exchange Act and none of the SEC Reports, when
filed, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading, except to
the extent corrected by subsequently filed documents with the
Commission. The financial statements of the Company included in the
SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the
Commission with respect thereto as in effect at the time of filing.
Such financial statements have been prepared in accordance with
United States generally accepted accounting principles applied on a
consistent basis during the periods involved (“ GAAP
”), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial
statements may not contain all footnotes required by GAAP, and
fairly present in all material respects the financial position of
the Company and its consolidated subsidiaries as of and for the
dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments.
(i) Material Changes;
Undisclosed Events, Liabilities or Developments . Since the
date of the latest audited financial statements included within the
SEC Reports, except as disclosed in the SEC Reports or described
in, or incorporated by reference into, the Registration Statement,
(i) there has been no event, occurrence or development that
has had or that would reasonably be expected to result in a
Material Adverse Effect, (ii) the Company has not incurred any
liabilities (contingent or otherwise) other than (A) trade
payables and accrued expenses incurred in the ordinary course of
business consistent with past practice and (B) liabilities not
required to be reflected in the Company’s financial
statements pursuant to GAAP or required to be disclosed in filings
made with the Commission, (iii) the Company has not altered
its method of accounting, (iv) the Company has not declared or
made any dividend or distribution of cash or other property to its
stockholders or purchased, redeemed or made any agreements to
purchase or redeem any shares of its capital stock and (v) the
Company has not issued any equity securities to any officer,
director or Affiliate, except pursuant to existing Company stock
option plans. The Company does not have pending before the
Commission any request for confidential treatment of information.
Except for the issuance of the Securities contemplated by this
Agreement, no event, liability or development has occurred or
exists with respect to the Company or the Subsidiary or their
respective business, properties, operations or financial condition,
that would be required to be disclosed by the Company under
applicable securities laws at the time this representation is made
that has not been publicly disclosed prior to the date of this
Agreement or described in, or incorporated by reference into, the
Prospectus Supplement.
(j) Litigation .
Except as described in Schedule 3.1(j) hereto, there is no
Proceeding against or affecting the Company, the Subsidiary or any
of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign) (collectively, an
“ Action ”) which (i) adversely affects or
challenges the legality, validity or enforceability of any of the
Transaction Documents or the Securities or (ii) would, if
there were an unfavorable
12
decision, reasonably be
expected to result in a Material Adverse Effect. Neither the
Company nor the Subsidiary, nor any director or officer thereof, is
or has been the subject of any Action involving a claim of
violation of or liability under federal or state securities laws or
a claim of breach of fiduciary duty. There has not been, and to the
knowledge of the Company, there is not pending or contemplated, any
investigation by the Commission involving the Company or any
current or former director or officer of the Company.
(k) Labor Relations .
No material labor dispute exists or, to the knowledge of the
Company, is imminent with respect to any of the employees of the
Company which would reasonably be expected to result in a Material
Adverse Effect. None of the Company’s or the
Subsidiary’ employees is a member of a union that relates to
such employee’s relationship with the Company or the
Subsidiary, and neither the Company nor the Subsidiary is a party
to a collective bargaining agreement, and the Company and the
Subsidiary believe that their relationships with their employees
are good. To the Company’s knowledge, (i) no executive
officer, to the knowledge of the Company, is, or is now expected to
be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or
non-competition agreement, or any other contract or agreement or
any restrictive covenant in favor of any third party, and
(ii) the continued employment of each such executive officer
does not subject the Company or the Subsidiary to any liability
with respect to any of the foregoing matters. The Company and the
Subsidiary are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and
employment practices, terms and conditions of employment and wages
and hours, except where the failure to be in compliance would not,
individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.
(l) Compliance .
Neither the Company nor the Subsidiary (i) is in default under
or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in
a default by the Company or the Subsidiary under), nor has the
Company or the Subsidiary received notice of a claim that it is in
default under or that it is in violation of, any indenture, loan or
credit agreement or any other agreement or instrument to which it
is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived),
(ii) is in violation of any order of any court, arbitrator or
governmental body, or (iii) is or has been in violation of any
statute, rule or regulation of any governmental authority,
including without limitation all foreign, federal, state and local
laws applicable to its business and all such laws that affect the
environment, except in each case as would not reasonably be
expected to result in a Material Adverse Effect.
(m) Regulatory Permits
. The Company and the Subsidiary possess all certificates,
authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities required to conduct
their respective businesses as described in the SEC Reports, except
where the failure to possess such permits would not reasonably be
expected to result in a Material Adverse Effect (“
Material Permits ”), and neither the Company nor the
Subsidiary has received any notice of proceedings relating to the
revocation or modification of any Material Permit.
13
(n) Title to Assets .
Except as described in, or incorporated by reference into, the
Registration Statement, the Company and the Subsidiary have good
and marketable title in fee simple to all real property owned by
them that is material to the business of the Company and the
Subsidiary and good and marketable title in all personal property
owned by them that is material to the business of the Company and
the Subsidiary, in each case free and clear of all Liens, except
for Liens as do not materially affect the value of such property
and do not materially interfere with the use made and proposed to
be made of such property by the Company and the Subsidiary and
Liens for the payment of federal, state or other taxes, the payment
of which is neither del
|